Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2021-02-05 Regulatory Filings
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number' and contains information about a 'Price Monitoring Extension' related to trading on the London Stock Exchange. It explicitly states that the information is provided by 'RNS, the news service of the London Stock Exchange' and is approved by the Financial Conduct Authority (FCA). This is a general regulatory announcement that does not fit into specific categories like earnings, annual reports, or director dealings. Therefore, it falls under the general Regulatory Filings category.
2021-02-05 English
Investment team changes
Board/Management Information Classification · 1% confidence The document explicitly announces changes in the company's investment team, specifically the resignation of a Managing Director (Jonathan Tobin, PhD) and commentary from the Executive Chairman regarding team expansion. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2021-01-18 English
Harpoon announces closing of public offering
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory announcement disseminated via EQS Group, originating from Arix Bioscience plc, noting that its portfolio company, Harpoon Therapeutics, has closed a public offering of common stock, raising approximately $115.0 million. This announcement details a significant financing/fundraising event for the portfolio company, which Arix is reporting on. The content directly relates to capital structure changes and fundraising activities. This aligns best with the 'Capital/Financing Update' category (CAP). Although it is a regulatory announcement, the specific subject matter (closing of a public offering) is more precise than the general 'RNS' fallback.
2021-01-12 English
Imara reports Phase 2a clinical trial results of IMR-687 in adult patients with sickle cell disease  
Regulatory Filings Classification · 1% confidence The document is an announcement disseminated via EQS Group, reporting on the Phase 2a clinical trial results for a drug (IMR-687) developed by Imara Inc., a portfolio company of Arix Bioscience plc. The text contains detailed clinical data, safety profiles, biomarker results, and future data release timelines (e.g., 'In the second half of 2021, Imara expects to report interim Phase 2b data'). This structure—a press release detailing specific scientific/clinical findings and future expectations—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses purely on clinical trial results and not overall financial performance (like revenue/net income), it is best classified as an announcement of scientific/clinical progress. However, given the options, this detailed release of period-specific results (clinical trial readout) aligns most closely with the function of an Earnings Release (ER), which often includes operational highlights, even if not strictly financial earnings. If it were just a link to a full report, it would be RPA/RNS. Since it contains the substantive results, ER is the most appropriate fit among the choices for a major operational update. Revisiting definitions: ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. While this is clinical data, it serves the same purpose as a periodic operational update. If this were a full, comprehensive report, it might be different, but as a press release announcing the results, ER is the closest fit for a major periodic update. If 'IR' (Interim Report) was for clinical data, that would be better, but IR is defined as a comprehensive financial report. Therefore, ER is chosen as the best fit for a major periodic operational/scientific highlight announcement.
2021-01-06 English
Autolus provides business outlook for 2021 and 2022
Earnings Release Classification · 1% confidence The document is a press release disseminated via EQS Group, originating from Arix Bioscience plc, announcing that its portfolio company, Autolus Therapeutics, has provided a business outlook for 2021 and 2022. It contains key operational updates, pipeline progress (AUTO1, AUTO3), expected data timelines, and management reorganization details. This structure—a brief announcement by one company referencing the operational/financial update of another, often including forward-looking statements and contact information—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses on providing key financial/operational guidance (outlook) rather than being a full, comprehensive quarterly report (IR) or a transcript (CT), 'ER' is the most appropriate fit for the initial release of period-specific guidance. However, the content is primarily an update on business strategy and pipeline milestones rather than core quarterly financial figures, which leans slightly towards a general regulatory announcement or an investor presentation summary. Given the context of providing a 'business outlook' which often accompanies or precedes formal earnings, and the fact that it is a formal regulatory announcement ('Dissemination of a Regulatory Announcement'), it fits best under the general 'Regulatory Filings' (RNS) category as a specific update that isn't a full financial report (IR/10-K) or a dedicated earnings release summary (ER). Since it is a formal regulatory announcement that doesn't fit the specific financial report types, RNS is the safest classification. Q1 2021
2021-01-06 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1920 characters) and contains the header 'RNS Number : 2689K'. It explicitly mentions 'RNS, the news service of the London Stock Exchange' and discusses a 'Price Monitoring Extension' related to trading rules. This is a brief, specific regulatory announcement disseminated via the RNS system, rather than a comprehensive report like a 10-K or IR. Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIV, DIRS, or ER), the most appropriate classification is the general regulatory filing category.
2020-12-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.